StockNews.com Begins Coverage on Evogene (NASDAQ:EVGN)

Research analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Lake Street Capital dropped their target price on Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Trading Up 3.0 %

EVGN stock opened at $1.37 on Thursday. The stock has a market cap of $7.36 million, a PE ratio of -0.31 and a beta of 1.36. Evogene has a 12 month low of $1.26 and a 12 month high of $10.40. The company has a 50-day moving average price of $1.99 and a 200 day moving average price of $3.86.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.